Jared Houk

AccendoWave - A Pain #Data Company #Medtronic has agreed to not only expand the size of its board of directors, but to also task it with taking a closer look at cutting costs and exploring more tuck-in M&A—after what it described as a “constructive dialogue” with the company’s newest stakeholder, Elliott Investment Management. https://lnkd.in/du8mwzCK

4

Rethinking Heart Failure Management—Why Device Innovation Matters Interesting article from the Cleveland Clinic - Device-Based Heart Failure Therapies in the Spotlight. It highlights the shift in how we address heart failure in today’s clinical landscape. The piece emphasizes that despite advances in pharmacotherapy, hospitalisation and mortality rates continue to climb—and that earlier consideration of device-based therapies is essential to alter disease trajectories effectively. This aligns with the latest consensus guidance from the HFSA, advocating a more integrated pathway that pairs guideline-directed medical therapy (GDMT) with device-based options for patients not fully responding to medications alone. From my perspective at Ceryx Medical, this trend holds deep relevance. Our device, designed to optimise cardiac function, improve energy efficiency and boost cardiac output thereby treating symptoms and inducing cardiac repair, dovetails with this evolving paradigm. Here’s why: Early intervention is key: By targeting the root of cardiac inefficiency sooner, our device aligns with the Cleveland Clinic’s call to shift device therapy “earlier” in the care continuum, particularly in NYHA II–III patients. Bridging gaps in GDMT response: For patients who remain symptomatic despite medical management our approach offers a powerful tool for eliminating the debilitating symptoms of heart failure. Enhancing personalization of care: The trend toward phenotype-driven treatment decisions, as outlined in recent reviews, mirrors our commitment to developing solutions that fit the individual patient’s physiology, symptom profile, and treatment tolerance. Complementary rather than competitive: Ceryx has demonstrated our technology significant improves the clinical condition of subjects already treated with optimal pharmacotherapy. In essence, this Cleveland Clinic article reinforces that advanced device strategies are not just “nice to have”—they’re becoming essential companions to pharmacological therapy in improving outcomes and quality of life for heart failure patients. #HeartFailure #MedicalDevices #DigitalHealth #ClinicalInnovation #Cardiology #GDMT #DeviceTherapy #PatientCentricCare

35